Sysmex Corporation (0YX) - Total Liabilities
Based on the latest financial reports, Sysmex Corporation (0YX) has total liabilities worth €186.25 Billion EUR as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sysmex Corporation - Total Liabilities Trend (2016–2025)
This chart illustrates how Sysmex Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sysmex Corporation Competitors by Total Liabilities
The table below lists competitors of Sysmex Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Delek Group
TA:DLEKG
|
Israel | ILA38.86 Billion |
|
Ryan Specialty Group Holdings Inc
NYSE:RYAN
|
USA | $9.31 Billion |
|
Mobile World Investment Corp
VN:MWG
|
Vietnam | ₫50.78 Trillion |
|
Tauron Polska Energia S.A.
WAR:TPE
|
Poland | zł26.20 Billion |
|
Flughafen Zuerich AG
LSE:0RG6
|
UK | £2.37 Billion |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
China | CN¥21.97 Billion |
|
Axos Financial Inc
NYSE:AX
|
USA | $24.64 Billion |
|
Ampol Limited
F:CLZ
|
Germany | €10.09 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Sysmex Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sysmex Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sysmex Corporation (2016–2025)
The table below shows the annual total liabilities of Sysmex Corporation from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €200.73 Billion | +7.91% |
| 2024-03-31 | €186.02 Billion | +30.34% |
| 2023-03-31 | €142.72 Billion | +5.99% |
| 2022-03-31 | €134.65 Billion | +13.34% |
| 2021-03-31 | €118.81 Billion | +7.09% |
| 2020-03-31 | €110.94 Billion | +35.97% |
| 2019-03-31 | €81.59 Billion | +1.31% |
| 2018-03-31 | €80.54 Billion | +15.77% |
| 2017-03-31 | €69.56 Billion | -12.55% |
| 2016-03-31 | €79.55 Billion | -- |
About Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematol… Read more